Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

By Haas N.   Roth B.   Garay C.   Yeslow G.   Entmacher M.   Weinstein A.   Rogatko A.   Babb J.   Minnitti C.   Flinker D.   Gillon T.   Hudes G.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 59-64

Elsevier

Access to resources Recommend Favorite

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial

By Gomella L.G.   Liberman S.N.   Mulholland S.G.   Petersen R.O.   Hyslop T.   Corn B.W.  

Urology, Vol. 47, Iss. 6, 1996-06 ,pp. : 870-877

Elsevier

Access to resources Recommend Favorite

A Survival Comparison of Mucin-Producing Adenocarcinoma of the Esophagus to Conventional Adenocarcinoma after Esophagectomy

By Zheng Dennis J.   Cooke David T.  

The American Surgeon, Vol. 79, Iss. 1, 2013-01 ,pp. : 49-53

Southeastern Surgical Congress

Access to resources Recommend Favorite

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy

By Ford SJ   Bedford MR   Pang W   Wood A   Iqbal T   Tselepis C   Tucker O  

Annals of The Royal College of Surgeons of England, Vol. 96, Iss. 4, 2014-05 ,pp. : 275-278

The Royal College of Surgeons of England

Access to resources Recommend Favorite

Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma

By Okegawa T.   Kato M.   Nutahara K.   Higashihara E.  

Urology, Vol. 57, Iss. 5, 2001-05 ,pp. : 936-942

Elsevier

Access to resources Recommend Favorite